Trial Profile
BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Ridaforolimus (Primary)
- Indications Colon cancer; Head and neck cancer; Non-small cell lung cancer
- Focus Adverse reactions
- 29 Jan 2021 Allocation changed from Non-Randomized to N/A.
- 22 Feb 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 22 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.